Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy

被引:37
作者
Guglielmi, Chiara [1 ]
Palermo, Andrea [1 ]
Pozzilli, Paolo [1 ,2 ]
机构
[1] Univ Campus Bio Med, Dept Endocrinol & Diabet, I-00128 Rome, Italy
[2] Queen Marys Univ London, Ctr Diabet, Barts & London Sch Med & Dent, London, England
关键词
LADA; epidemiology; pathogenesis; therapy; BETA-CELL-MASS; GLUTAMIC-ACID DECARBOXYLASE; DOUBLE-BLIND; GENETIC-CHARACTERISTICS; ROSIGLITAZONE PREVENTS; INSULIN INTERVENTION; HIGH-TITER; AUTOANTIBODIES; IMMUNOMODULATION; PIOGLITAZONE;
D O I
10.1002/dmrr.2345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action or both. An effect of this process is chronic hyperglycaemia with disorder of carbohydrate, fat and protein metabolism and with long-term complications of diabetes including retinopathy, nephropathy and neuropathy. Latent autoimmune diabetes in adults (LADA) is a type of autoimmune diabetes that resembles Type 1 diabetes (T1D), however, it shows a later onset and slower progression towards insulin necessity. Epidemiological studies suggest that LADA may account for 212% of all cases of diabetes in adult population. The epidemiology and phenotypic characteristics of LADA may vary between Caucasian and Asian diabetic patients as lifestyle, food habits and body mass index differ between these two populations. Data on LADA from population-based studies in Asia are sparse and only few studies have looked at it. A number of attractive therapeutic interventions may be envisaged for prevention of beta-cell loss in LADA, including hypoglycaemic and immunomodulatory agents. Because the autoimmune process in LADA seems to be slower than in childhood T1D, there is a wider window of opportunities for intervention. In deciding the best therapeutic approach, features of LADA should guide therapy including presence of other comorbidities that may influence the therapeutic choice.
引用
收藏
页码:40 / 46
页数:7
相关论文
共 64 条
  • [1] Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes
    Agardh, CD
    Cilio, CM
    Lethagen, Å
    Lynch, K
    Leslie, RDG
    Palmér, M
    Harris, RA
    Robertson, JA
    Lernmark, Å
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2005, 19 (04) : 238 - 246
  • [2] American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5
  • [3] INSULIN SUPPRESSES ITS OWN SECRETION INVIVO
    ARGOUD, GM
    SCHADE, DS
    EATON, RP
    [J]. DIABETES, 1987, 36 (08) : 959 - 962
  • [4] PREVENTION OF ADOPTIVE TRANSFER IN BB RATS BY PROPHYLACTIC INSULIN-TREATMENT
    BERTRAND, S
    DEPAEPE, M
    VIGEANT, C
    YALE, JF
    [J]. DIABETES, 1992, 41 (10) : 1273 - 1277
  • [5] NOD mouse diabetes: The ubiquitous mouse Hsp60 is a beta-cell target antigen of autoimmune T cells
    Birk, OS
    Elias, D
    Weiss, AS
    Rosen, A
    vanderZee, R
    Walker, MD
    Cohen, IR
    [J]. JOURNAL OF AUTOIMMUNITY, 1996, 9 (02) : 159 - 166
  • [6] Bonifacio E, 1998, J IMMUNOL, V161, P2648
  • [7] ISLET AUTOANTIBODY MARKERS IN IDDM - RISK ASSESSMENT STRATEGIES YIELDING HIGH-SENSITIVITY
    BONIFACIO, E
    GENOVESE, S
    BRAGHI, S
    BAZZIGALUPPI, E
    LAMPASONA, V
    BINGLEY, PJ
    ROGGE, L
    PASTORE, MR
    BOGNETTI, E
    BOTTAZZO, GF
    GALE, EAM
    BOSI, E
    [J]. DIABETOLOGIA, 1995, 38 (07) : 816 - 822
  • [8] BONIFACIO E, 1995, J IMMUNOL, V155, P5419
  • [9] Latent autoimmune diabetes in adults in a South Asian population of the UK
    Britten, Abigail C.
    Jones, Karen
    Toern, Carina
    Hillman, Magnus
    Ekholm, Birgitte
    Kumar, Sudhesh
    Barnett, Anthony H.
    Kelly, Marilyn Ann
    [J]. DIABETES CARE, 2007, 30 (12) : 3088 - 3090
  • [10] Brophy S, 2007, COCHRANE DB SYST REV, V3